Resolution, Therapeutics

Resolution Therapeutics Receives MHRA Approval to Commence Phase I/ II EMERALD Study for Lead Candidate RTX001

Published on 08/07/2025 at 18:07 | prnewswire.co.uk

Resolution Therapeutics United Kingdom United States of America Scotland

View original content:https://www.prnewswire.co.uk/news-releases/resolution-therapeutics-receives-mhra-approval-to-commence-phase-iii-emerald-study-for-lead-candidate-rtx001-302183739.html

en | boerse | 67949174 |